UroGen Pharma Expands Team with Inducement Grants
UroGen Pharma Ltd., a biotech innovator focused on treating urothelial and specialty cancers, recently took a significant step by granting inducement restricted stock units (RSUs) to 14 new employees. These grants are an essential part of their strategy to enhance their workforce, ensuring that they remain at the forefront of development and commercialization of innovative cancer therapies.
Supporting Ongoing Commercialization Efforts
The addition of these new team members comes at a crucial time as UroGen continues to market its key products: Jelmyto and ZUSDURI™. Both products represent significant advancements in the treatment of urological conditions, specifically for pyelocalyceal and intravesical solutions, respectively. By strengthening their team, UroGen aims to improve their marketplace presence and efficacy in providing better treatment options for patients.
Grant Details and Vesting Schedule
The inducement grants include the potential issuance of up to 32,500 ordinary shares of UroGen, which will vest over a period of three years. The structured vesting, occurring in equal installments, aligns with the employees' continued service, ensuring that the interests of the team are in sync with the company’s long-term goals.
UroGen’s Inducement Plan
These RSUs granted to the new hires are governed by UroGen's 2019 Inducement Plan. This plan is designed to attract talented individuals and reward them for their dedication and contributions. Compliance with Nasdaq Listing Rule 5635(c)(4) further solidifies the legitimacy and significance of this initiative.
About UroGen Pharma Ltd.
UroGen is a dedicated biotech firm passionately working towards innovative cancer treatments. With a focus on urothelial and specialty cancers, the company recognizes the pressing need for more effective treatment options. Their proprietary technology, including the RTGel reverse-thermal hydrogel, exemplifies their commitment to improving patient care. This sustained-release technology enables longer medication exposure, potentially enhancing therapeutic outcomes significantly.
UroGen’s Product Portfolio
UroGen's first commercially available product is specifically designed to treat low-grade upper tract urothelial cancer, while their second product holds the distinction of being the first FDA-approved treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both solutions aim to provide non-surgical alternatives for tumor ablation, showcasing UroGen's innovative approach to urological oncology.
UroGen's Commitment to Innovation
Headquartered in Princeton, the company operates not only in the United States but also in Israel, broadening its reach and impact in the field of oncology. Their mission reflects a deep understanding of patient needs, driving them to develop safer and more effective treatments over existing options.
Contact Information
For those interested in learning more about UroGen, whether you're a potential investor or simply seeking more information about their groundbreaking work, you can reach out to their investor contacts. Vincent Perrone is available for inquiries at (609) 460-3588 or via email at vincent.perrone@urogen.com. For media inquiries, contact Cindy Romano at (609) 460-3583 or through her email at Cindy.romano@urogen.com.
Frequently Asked Questions
What are the inducement grants announced by UroGen Pharma?
The inducement grants are restricted stock units (RSUs) awarded to new employees as part of their employment package.
How many employees received the RSUs?
UroGen granted RSUs to 14 new team members to enhance their workforce.
What is UroGen's primary focus?
UroGen focuses on developing and commercializing innovative solutions for the treatment of urothelial and specialty cancers.
Where is UroGen headquartered?
UroGen is based in Princeton, New Jersey.
What are UroGen's key products?
The company's notable products include Jelmyto and ZUSDURI™, which tackle various urological conditions.
